Biomerica, Inc. BMRA 深 滬
等待開盤 07-18 09:30:00 美东时间
3.40
+0.250
+7.94%
華盛通- 最 高3.44
- 今 開3.18
- 成交量 11.09万股
- 最 低 3.09
- 昨 收 3.15
- 總市值 865.57万
- 52周最高 10.16
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.932
- 委 比 96.88%
- 總股本 254.58万
- 歷史最高 187.12
- 量 比 0.70
- 振 幅 11.11%
- 歷史最低 1.932
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported Earlier: Biomerica Has Been Granted Canadian Patent Number 3145879 Titled "COMPOSITIONS, DEVICES, AND METHODS OF IBS SENSITIVITY TESTING".
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3145879/summary.html
07-11 09:03
InFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
Biomerica, Inc. announced that the American Medical Association has issued a new CPT® code for its inFoods® IBS test, enabling insurance reimbursement and expanded patient access. The test identifies personalized food triggers to alleviate IBS symptoms like bloating, pain, diarrhea, and constipation, offering a non-drug solution. Biomerica’s CEO and CCO highlighted the PLA code milestone as a step toward broader adoption and improved patient outc...
07-02 12:08
Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica Inc. appoints Scott Madel as Chief Commercial Officer, leveraging his 20+ years of experience in healthcare diagnostics and organizational growth. Madel successfully led turnarounds and scaled revenues at Boston Heart Diagnostics and Genova Diagnostics. He will drive commercialization of inFoods® IBS, a diagnostic-guided therapy for identifying food triggers in gastrointestinal conditions. Published clinical trials demonstrate its effic...
06-26 12:19
Biomerica Appoints Eric B. Chin to Board
Biomerica ( ($BMRA) ) has issued an update. On June 4, 2025, Cathy Coste resign...
06-06 21:47
Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair
Biomerica appoints Eric B. Chin to its Board of Directors, effective June 4, 2025. Mr. Chin, with over 20 years of financial experience in healthcare, will serve as Chair of the Audit Committee and member of other key committees. Currently Akido Labs' CFO, he helped raise $60 million in a recent financing. His加入加强了Biomerica的公司治理和财务监督，支持其商业化扩展。Biomerica is a global biomedical companydeveloping advanced diagnostic and therapeutic products,including...
06-06 13:30
Biomerica's inFoods IBS Test Featured In Prestigious Journal Gastroenterology As Landmark Peer-Reviewed Study Demonstrates Symptom Improvement In IBS Patients Through Personalized, Non-Drug Dietary Therapy
Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test.Gastroenterology, the premier journal in gastrointestinal science, features data
06-05 20:20
Biomerica’s inFoods® IBS Clinical Study Results Published in June Issue of Gastroenterology
<p>A peer-reviewed study published in <em>Gastroenterology</em> highlights the effectiveness of inFoods® IBS Test, a personalized dietary therapy for IBS patients. Conducted across eight U.S. academic centers, the trial involving 238 participants demonstrated that patients following a diet guided by the inFoods IBS test experienced significant symptom improvement, particularly in abdominal pain and bloating. The study found that 59.6% of the trea...
06-05 12:19
Biomerica Announces Real-World Results Showing Effectiveness Of inFoods IBS Product, Along With Launch Of Proprietary Real-Time Patient Feedback System To Enhance Symptom Tracking And Improve Patient Outcomes
Real-World Impact: Initial data from over 360 patients shows inFoods® IBS delivered an average 48.5% reduction in gastrointestinal pain and a 49.8% reduction in bloating over an 8-week period First-of-Its-Kind
05-22 20:22
Announces The Co And Its CLIA Laboratory Partner Have Submitted An Application To The American Medical Association CPT Editorial Panel Requesting The Assignment Of A Proprietary Laboratory Analysis Code For The InFoods IBS Diagnostic Test
- Application represents milestone toward broadening patient access to inFoods IBS- inFoods® IBS pinpoints patient-specific foods that can trigger IBS symptoms like bloating, abdominal pain, diarrhea, and
05-07 20:22
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers icad (NASDAQ:ICAD) stock moved upwards by 73.0% to $3.34 during Wednes...
04-17 01:06
